Compound
The composition depends on the form of release of the medical product.
For example, Nott's drops contain 10 ml of extracts of phosphorus, chamomile, coffee tree, zinc valerate , as well as 20 ml of seed oats . ethyl alcohol as an auxiliary component .
Nott's tablets contain 37.2 mg of zinc valerate, chamomile, phosphorus, coffee tree and 74.5 mg of oats . Among the auxiliary components in the tablet form of the drug are potato starch, magnesium stearate and lactose monohydrate .
Pharmacological properties
Pharmacodynamics.
Notta reduces anxiety, fear, irritability, nervous tension and restlessness. has a pronounced stress-protective effect. It has a positive effect on the course of neurovegetative disorders: it reduces the frequency and intensity of attacks of headaches, dizziness, rapid heartbeat and cardiac arrhythmias, nausea, difficulty breathing, a feeling of a “coma” in the throat, pain in the chest and epigastrium that arise as a result of nervous strain.
Normalizes sleep: makes it easier to fall asleep, improves the quality of night sleep, reduces the number of night awakenings; promotes the restoration of physiological sleep and the daily sleep-wake cycle, while not causing difficulty in awakening or drowsiness during the day.
Reduces the severity of asthenia (lethargy, increased fatigue). Increases concentration, ability to think clearly, improves memory.
Notta improves individual compensatory mental capabilities, performance, and resistance to psycho-emotional stress.
Pharmacokinetics. Not studied.
Release form
Notta is produced in the form of drops (a clear, yellowish or greenish liquid, odorless), which are packaged in glass bottles (20, 50 and 100 ml), equipped with a dropper for ease of use. Then the medicine is placed in cardboard boxes, one bottle in each.
Tablets (flat-cylindrical round shape, chamfered and scored, odorless, white or yellowish with inclusions) are packaged in blisters of 12 pcs. in each, and then placed in a cardboard pack of 1, 2, 3 and 4 blisters in each.
Indications
In the complex treatment of psychosomatic disorders and any conditions after suffering nervous strain or stress, accompanied by restlessness, anxiety, depression, sleep disturbances, and nervous exhaustion.
In pediatrics: in the complex treatment of the consequences of perinatal damage to the central nervous system, hypertensive liquorodynamic syndrome, neurogenic bladder syndrome, autonomic dysfunction syndrome, asthenic symptom complex of various etiologies and syndrome of increased neuro-reflex excitability.
Indications for use
The drug in the form of drops is effective for feelings of fear and increased anxiety, for vegetative type lability (rapid heartbeat, sweating, etc.), for increased fatigue, sleep disturbances and irritability , for psycho-emotional tension , as well as for psychosomatic and nervous disorders and mood lability.
Nott's tablets are used in the treatment of psychosomatic and neurosis-like disorders, which are accompanied by sleep disturbances, anxiety and nervous tension.
Pharmachologic effect:
Notta is a complex homeopathic remedy for the treatment of sleep disorders and increased nervous excitability. Has an anxiolytic effect. Improves tolerance to emotional and mental stress. Helps normalize physiological sleep rhythms. The action is due to the combined effect of all its components, so pharmacokinetic studies are impossible (it is impossible to trace the biometabolites of the drug or determine kinetics using biological studies or markers).
Instructions for Notta (Method and dosage)
The medication is taken orally at least half an hour before meals.
Notta drops, instructions for use
To improve the medicinal effect, the drops should be kept in the mouth for a while and then swallowed. It is not forbidden to dissolve drops in water. The average dosage of the drug for adult patients and adolescents is 10 drops three times a day. Children aged 3 to 12 years – 5 drops three times a day.
As a rule, the duration of the course of therapeutic treatment lasts from 1 to 4 months. In traumatic situations, the course of treatment can last 1-4 weeks.
Notta tablets, instructions for use
For the greatest effectiveness of the drug, the tablets are placed under the tongue until completely absorbed. The daily dosage for adult patients and adolescents is 1 tablet three times a day. The course of treatment can last from 1 to 4 months, and in the case of a traumatic situation - from 1 to 4 weeks.
If necessary to immediately relieve symptoms of nervous disorders or at the beginning of a course of treatment, drops can be taken every 30 minutes or hour:
- children aged 3 to 12 years, 3-5 drops;
- adult patients and adolescents – 8-10 drops (corresponds to 1 tablet).
The above-described “emergency” treatment regimen is used until the condition improves, then the drug should be taken no more than 3 times a day.
Instructions for Notta for children
For the therapeutic treatment of patients aged 3 to 12 years, drops are used that can be diluted in water. The medicine should be taken 3 times a day in a maximum dosage of 5 drops.
Notta 5mg No. 28 tablets
Notta 5mg No. 28 tablets
Name NOTTA-sanovel
International name Montelukast
Dosage form Chewable tablets 5 mg
Composition One tablet contains the active substance: montelukast sodium 5.2 mg (equivalent to montelukast 5.0 mg), excipients: mannitol, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, sodium saccharin, magnesium stearate, cherry flavor, iron (III) oxide red E172.
Description of the appearance of the drug, tablets Round, pink tablets, without marks.
Pharmacological group of the drug Other drugs for the treatment of obstructive respiratory diseases for systemic use. Leukotriene receptor antagonists. Montelukast. ATX code R03DC03
Pharmacological properties Pharmacokinetics When administered orally, montelukast is rapidly absorbed from the gastrointestinal tract. After oral administration of 5 mg of the drug on an empty stomach in adult patients, the average peak plasma concentration is reached within 2-2.5 hours. Montelukast is more than 99% bound to plasma proteins. The volume of distribution averages 8 – 11 liters. Bioavailability when taken orally is 64%. Montelukast is actively metabolized in the liver. In vitro studies using liver microsomal enzymes have shown that cytochrome P450 3A4 and 2C9 are involved in the metabolism of montelukast. The half-life is 2.7–5.5 hours. The pharmacokinetics of montelukast in doses up to 50 mg is almost linear. After taking 10 mg of montelukast once daily, moderate accumulation was observed (plasma concentration of the active substance was approximately 14%). Clearance in healthy adults is approximately 45 ml/min. Montelukast and its metabolites are almost completely excreted in the bile. The pharmacokinetics and bioavailability of a single 10 mg oral dose of montelukast are similar in the elderly and young. The half-life of montelukast is slightly longer in the elderly, but no dose adjustment is required in this age group. In patients with mild to moderate hepatic impairment and cirrhosis, after taking a single dose of montelukast 10 mg, the mean area under the curve was 41% greater, and elimination was slightly longer than in healthy volunteers (mean half-life 7.4 hours). No dose adjustment is required in patients with mild to moderate hepatic impairment. The pharmacokinetics of montelukast in patients with severe hepatic impairment or hepatitis have not been studied. Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast have not been studied in patients with renal impairment. No dose adjustment is required in these patients. In pharmacokinetic studies in children 2–5 years of age, the AUC following a single 4 mg dose was similar to that following a single 10 mg dose in adults. Pharmacodynamics NOTTA-sanovel is an orally active, selective leukotriene receptor antagonist with high affinity for cysteinyl leukotriene receptors (CysLT1). Cysteinyl leukotrienes (LTC4, LTD4, LTE4) are inflammatory eicosanoids secreted by mast cells and various other cells, including eosinophils. These important proasthmatic mediators bind to cysteinyl leukotriene receptors (CysLT1) in the airways and cause effects such as bronchoconstriction, mucus hypersecretion, increased vascular permeability and eosinophil accumulation. Cysteinyl leukotrienes play an important role in the development of symptoms of allergic rhinitis. In the early and late phases of an allergic reaction after exposure to an allergen, cysteinyl leukotrienes are released in the nasal mucosa. Their effect is manifested in worsening nasal cavity patency and increased nasal congestion. Clinical studies have shown the effectiveness of the drug in the symptomatic treatment of seasonal allergic rhinitis. Montelukast, exhibiting high affinity, selectively binds to CysLT1 receptors (instead of other pharmacologically significant receptors of the respiratory tract, such as prostanoid receptors, cholinergic or β-adrenergic receptors) and, thus, inhibits the physiological effect of LTD4. In clinical studies, montelukast in small doses up to 5 mg inhibited bronchoconstriction induced by inhaled LTD4. Bronchodilation was observed within 2 hours after oral administration. Montelukast inhibited bronchoconstriction, reducing the severity of early and late phase allergic reactions caused by antigen exposure.
Indications for use - prevention and treatment of bronchial asthma, including prevention of daytime and nighttime symptoms of the disease in children 6-14 years old, including “aspirin” asthma, exercise-induced bronchial asthma - prevention and treatment of daytime and nighttime symptoms of seasonal allergic rhinitis in children 6-14 years old
Methods of administration If the attending physician does not prescribe another regimen for taking the drug, the following dosage regimen is used. For children 6-14 years of age with bronchial asthma or seasonal allergic rhinitis, the daily dose is 5 mg (one chewable tablet) at bedtime. The drug must be taken 1 hour before or 2 hours after meals. The duration of the course of treatment is determined by the attending physician. General recommendations The therapeutic effect of NOTTA-sanovel on indicators reflecting the course of bronchial asthma develops during the first day. The patient should continue to take NOTTA-sanovel both during the period of achieving control over the symptoms of bronchial asthma and during periods of exacerbation of bronchial asthma. For the elderly, patients with renal or mild to moderate hepatic impairment, no dosage adjustment is required. Used together with other drugs for the treatment of bronchial asthma, NOTTA-sanovel can be added to the patient’s existing treatment regimen. Bronchodilators For patients in whom monotherapy with bronchodilators has not provided sufficient control, NOTTA-sanovel should be added to treatment. After clinical response is obtained (mostly after the first dose), the dose of bronchodilators can be reduced to the desired level. Inhaled corticosteroids In patients taking inhaled corticosteroids, the use of NOTTA-sanovel provides additional clinical benefit. The dose of the corticosteroid can be reduced to a tolerated level under the supervision of a physician. In some patients, inhaled corticosteroids can be discontinued after dose reduction. NOTTA-sanovel should not be used immediately instead of inhaled corticosteroids.
Side effects Very often: - respiratory tract infections (sinusitis, pharyngitis, laryngitis, otitis media, influenza) Often: - increased body temperature - nausea, vomiting, dyspepsia, dry mouth, diarrhea - increased levels of transaminases (ALT, AST) in the blood serum - hypersensitivity reactions (anaphylaxis, itching, urticaria) - headache, abnormal dreams, including nightmares, drowsiness, insomnia, somnambulism, psychomotor hyperactivity, irritability, anxiety, aggressive behavior, hostility, depression, tremor, paresthesia/hypoesthesia, fatigue - muscle cramps, myalgia, arthralgia - epistaxis, hematomas - edema Rarely - systemic eosinophilia, symptoms of vasculitis (similar to Churg-Strauss syndrome when treated with systemic corticosteroids. These cases are mainly associated with a decrease in the dose of oral corticosteroids). - angioedema - tachycardia - impaired attention, memory impairment - increased tendency to bleeding Very rarely - pancreatitis - eosinophilic infiltration of the liver, hepatitis - hallucinations, disorientation, suicidal intentions - erythema nodosum, erythema multiforme
Contraindications - hypersensitivity to montelukast or any other component of the drug - children under 6 years of age - phenylketonuria - pregnancy and lactation
Drug interactions NOTTA-sanovel can be used with other drugs for the prevention and long-term treatment of asthma without increasing side effects. During drug interaction studies, NOTTA-sanovel at the recommended dose did not cause clinically significant changes in the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg / ethinyl estradiol 35 mcg), terfenadine, digoxin, warfarin. Although specific drug interaction studies have not been conducted, NOTTA-sanovel has been used with various drugs in clinical studies. These include medications such as thyroid hormones, sedative-hypnotics, nonsteroidal anti-inflammatory drugs, benzodiazepines, and decongestants. Phenobarbital, when used simultaneously with a single dose of NOTTA-sanovel 10 mg, caused a decrease in the area under the NOTTA-sanovel curve by approximately 40%. No dose adjustment of NOTTA-sanovel is required when used in combination with Phenobarbital. Preparations containing St. John's wort may reduce the level of montelukast in the blood plasma.
Special instructions General NOTTA-sanovel is not intended for the relief of bronchospasm during acute attacks of asthma, nor for the treatment of status asthmaticus. In acute cases of bronchial asthma, it is recommended to use appropriate medications to treat patients. In the acute phase of bronchial asthma, treatment with NOTTA-sanovel can be continued. Even with a gradual, controlled reduction in the dose of an inhaled glucocorticosteroid, NOTTA-sanovel should not be immediately prescribed instead of an inhaled corticosteroid. Patients with exercise-induced asthma should continue to use inhaled β-agonists for prevention and should also have a short-acting β-agonist available to control attacks. Patients with aspirin-induced asthma should not take aspirin or other non-steroidal anti-inflammatory drugs while using NOTTA-sanovel. NOTTA-sanovel improves airway patency in patients with aspirin-induced asthma. Eosinophilic conditions In patients with bronchial asthma taking NOTTA-sanovel, systemic eosinophilia is rarely possible, and symptoms of vasculitis similar to Churg-Strauss syndrome may sometimes be observed when treated with systemic corticosteroids. These cases are mainly associated with a reduction in the dose of oral corticosteroids. The physician should be alert for the presence of eosinophilia, vasculitis, respiratory symptoms, cardiac complications, or neuropathy. Although no causal relationship was found between the use of NOTTA-sanovel and these conditions. Use in pediatrics Appropriate controlled studies in children 6–14 years of age have confirmed the effectiveness and safety of montelukast. The efficacy and safety profiles obtained in this age group are similar to those in adults. Placebo-controlled studies have shown the safety of 4 mg chewable tablets in children 2–5 years of age. Studies have confirmed the safety of the use of chewable tablets 4 mg and 5 mg in children 2–14 years old, both with bronchial asthma and seasonal allergic rhinitis. In safety studies in children 2–14 years of age with seasonal allergic rhinitis, the safety profile was similar. The effectiveness and safety of montelukast in children under 24 months of age have not been studied. Use in the elderly Clinical studies have shown no differences between young and elderly volunteers in terms of the safety and effectiveness of montelukast. Features of the effect of the drug on the ability to drive vehicles and machinery. NOTTA-sanovel can cause headache, drowsiness, lethargy, and slowness. This should be taken into account if it is necessary to use the drug in persons whose activities involve driving a car or servicing machines and mechanisms.
Overdose Symptoms: dehydration, drowsiness, mydriasis, hyperkinesia, abdominal pain. Treatment: removal of unabsorbed drug from the gastrointestinal tract, clinical observation, maintenance therapy. It is unknown whether montelukast is eliminated by hemodialysis or peritoneal dialysis.
Release form and packaging 14 tablets in a blister pack made of aluminum foil. 2 contour packages together with instructions for use in the state and Russian languages are placed in a cardboard pack.
Storage conditions Store in a dry place, protected from light, at a temperature not exceeding 25°C. Keep out of the reach of children!
Shelf life: 2 years Do not use after expiration date
Conditions for dispensing from pharmacies By prescription
Reviews of Notte
Patients who have tried this homeopathic drug on themselves leave different reviews about Nott's drops, as well as about the tablet form of the drug. This medicine has helped many, but for some it has been a disappointment.
Parents buy Nott's drops for their children; the majority of reviews about the drug are good, noting the effectiveness of the homeopathic remedy in normalizing children's sleep.
In addition, the medicine helps to reduce the child’s increased excitability and fatigue , eliminate attention disorder syndrome and cope with restlessness .
Note!
The description of the drug Notta on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use. Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug).
Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.
Notta price, where to buy
The average price of Notta in tablets (pack of 12 pcs.) is 200-220 rubles, in drops (bottle with a nominal volume of 20 ml) – 140-200 rubles.
- Online pharmacies in RussiaRussia
- Online pharmacies in UkraineUkraine
ZdravCity
- Notta drops homeopath.
50mlBittner Richard Gmbh RUR 438 order
Pharmacy Dialogue
- Notta bottle 20mlBittner Richard
RUB 285 order
- Notta bottle 50mlBittner Richard
RUR 449 order
show more
Pharmacy24
- Notta No. 48 tablets Richard Bittner AG, Austria
211 UAH.order - Notta No. 12 tablets Richard Bittner AG, Austria
86 UAH order
- Notta 50 ml drops Richard Bittner AG, Austria
182 UAH order
special instructions
The drug notta does not cause lethargy, daytime drowsiness, disturbances of consciousness or sexual function, therefore it can be recommended for representatives of any professions, including those requiring increased attention, rapid motor and mental reactions.
At the beginning of treatment, there may be manifestations of a slight increase in the severity of symptoms of the disease (primary reaction). This reaction is not harmful and does not require discontinuation of the drug. If symptoms do not disappear, use of the drug should be discontinued. After the initial reaction disappears, the drug can be used again. If symptoms worsen again, use of the drug should be discontinued.
Since Notta contains natural plant components, during storage there may be a slight change in taste, clarity or color, which does not lead to a decrease in the effectiveness of the drug.
Notta in tablet form contains lactose, so patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should take the drug in the form of drops instead of Notta tablets.
Notta's drug in the form of drops should not be used in patients with alcohol dependence, since one dose (5/10 drops) contains 80/160 mg of alcohol.
The alcohol content should also be taken into account when used during pregnancy, breastfeeding, children and patients with a high risk of liver disease and the risk of epileptic attacks.
Long-term treatment with homeopathic medicines should be monitored by a homeopathic physician, as symptoms may occur that are not listed in the instructions for use.
Use during pregnancy or breastfeeding. There are no data on the use of the drug during pregnancy and lactation. Information about any risk to the fetus and child from using the drug during pregnancy and breastfeeding has not yet been registered. The drug should be used during pregnancy and lactation only in cases where the expected benefit to the mother outweighs the possible risk to the fetus/child.
There are no data on the effect of the drug on reproductive function.
The ability to influence reaction speed when driving vehicles or other mechanisms. Despite the alcohol content, the drug in recommended doses does not affect the ability to drive vehicles and mechanical vehicles.
Interactions
No clinically significant interaction of Notta with other drugs has been established. it can be combined with any drugs and treatment methods.
When using Notta's drug simultaneously with psychotropic drugs (including tranquilizers, sleeping pills), the doses of the latter can be reduced under the supervision of a physician. In complex therapy with other drugs, pauses between doses of drugs should be at least 20 minutes.
An unhealthy lifestyle, use of stimulants, and poor nutrition negatively affect the results of using homeopathic medicines.
